Travere Therapeutics (TVTX) Net Equity Issued and Repurchased (2013 - 2022)
Travere Therapeutics' (TVTX) quarterly Net Equity Issued and Repurchased came in at -$20.1 million in Q4 2022, down 110.9% YoY from $184.4 million in Q4 2021, and down 200.0% on a QoQ basis from $20.1 million in Q1 2022.
Travere Therapeutics (TVTX) Net Equity Issued and Repurchased (2013 - 2022) Analysis & Trends
Travere Therapeutics (TVTX) has 6 years of Net Equity Issued and Repurchased data on file, last reported at -$20.1 million in Q4 2022.
- Quarterly Net Equity Issued and Repurchased fell 110.9% year-over-year to -$20.1 million in Q4 2022, while the trailing twelve-month figure through Sep 2022 was $204.5 million (up 354.63% YoY) and the FY2024 annual result came in at $134.7 million, down 29.53% from the prior year.
- Net Equity Issued and Repurchased fell to -$20.1 million in Q4 2022, from $20.1 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $184.4 million in Q4 2021 to a low of -$85.2 million in Q4 2020.
- A 3-year average of $26.6 million and a median of $2.4 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased soared 316.45% — and 2022, when it sank 110.9%.
- Tracing TVTX's Net Equity Issued and Repurchased over 3 years: stood at -$85.2 million in 2020, then soared by 316.45% to $184.4 million in 2021, then tumbled by 110.9% to -$20.1 million in 2022.
- The last three Net Equity Issued and Repurchased figures came in at -$20.1 million (Q4 2022), $20.1 million (Q1 2022), and $184.4 million (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -20.10 Mn |
| Dec 31, 2022 | -20.10 Mn |
| Mar 31, 2022 | 20.10 Mn |
| Mar 31, 2022 | 20.10 Mn |
| Dec 31, 2021 | 184.40 Mn |
| Dec 31, 2021 | 184.40 Mn |
| Jun 30, 2021 | -22,000.00 |
| Jun 30, 2021 | -22,000.00 |
| Mar 31, 2021 | 4.90 Mn |
| Mar 31, 2021 | 4.90 Mn |
| Dec 31, 2020 | -85.19 Mn |
| Dec 31, 2020 | -85.19 Mn |
| Sep 30, 2020 | -8,000.00 |
| Sep 30, 2020 | -8,000.00 |
| Jun 30, 2020 | 108.70 Mn |
| Jun 30, 2020 | 108.70 Mn |
| Dec 31, 2015 | 33,000.00 |
| Dec 31, 2015 | 33,000.00 |
| Mar 31, 2015 | 149.45 Mn |
| Mar 31, 2015 | 149.45 Mn |